 zoladex versu orchiectomi treatment advanc prostat cancer random trial zoladex prostat studi group preliminari result first patient multicent studi endocrin effect efficaci safeti mg goserelin acet zoladex patient stage prostat cancer patient zoladex median follow-up time patient hundr ten day median serum level testosteron level ng/dl week group week object respons criteria nation prostat cancer project percent percent patient zoladex orchiectomi group signific differ treatment group distribut time treatment failur time progress advers event treatment group hot flash cancer-rel pain unspecifi pain urinari symptom result zoladex altern treatment advanc prostat cancer